addition, allelic variants of the APOE gene may influence the course of several neurological diseases, like multiple sclerosis and motor neuron disease. 1, 7 The role of the APOE gene as a genetic risk factor for aneurysmal SAH has not been adequately investigated. In a small prospective study, Kokubo et al. 13 found that the risk of aneurysmal SAH was increased 2.5-fold in patients carrying the APOE ⑀4 allele. In contrast, the authors of two subsequent studies were unable to replicate these findings. 23, 26 Furthermore, researchers who have investigated the association between APOE genotypes and outcome after aneurysmal SAH have reported conflicting results. Results of some studies have shown that carrying the APOE ⑀4 allele is associated with significantly poorer clinical and neurological outcomes, whereas others have shown no significant gene effects. 6, 14, 17, 19, 26 To further evaluate whether a particular allele or genotype of the APOE gene affects the occurrence or the clinical features of aneurysmal SAH, we performed a case-control association study in a cohort of patients recruited from an Italian university-based neurosurgical clinic and in healthy controls.
Clinical Material and Methods

Patient Population
A total of 146 consecutive unrelated patients (46 men and 100 women; mean age at admission 53.5 Ϯ 14.2 years, mean age at hemorrhage 52.2 Ϯ 14.9 years [Ϯ SD]) admitted to the Division of Neurosurgery of the University of Turin in Italy between January 2002 and December 2004, were included in the study. The diagnosis of aneurysmal SAH was made according to the presence of symptoms suggestive of SAH combined with the finding of subarachnoid blood on CT and a proven aneurysm on conventional angiography. The CT findings were classified according to the grading system of Fisher et al. 8 Patients with genetic defects (such as Turner syndrome, Marfan syndrome, Ehlers-Danlos syndrome Type IV) known to be associated with an increased risk of IA were excluded from this study. The patients' clinical condition on admission was rated according to the Hunt and Hess grading scale. 12 For additional statistical analyses, patients were divided into the following three subgroups: single versus multiple aneurysms, according to the results of conventional angiography; anterior or posterior circulation aneurysms; and development of secondary cerebral ischemia, defined as a gradual decline in the level of consciousness or a gradual development of new focal deficits with the confirmation of a new hypodensity on CT.
Outcome was assessed 6 months after SAH with the GOS 31 by a neurosurgeon blinded to the APOE genotype. A standardized record of all the clinical characteristics of the patients, suitable for computer analysis, was obtained.
A group of 222 geographically matched healthy individuals (88 men and 134 women, mean age 57.3 Ϯ 13.5 years [Ϯ SD]) served as controls. Table 1 shows the demographic and clinical characteristics of aneurysmal SAH patients and healthy controls. The study was approved by the hospital ethics committee, and informed consent was obtained from all participants prior to the assessment.
Genotyping of APOE
Genomic DNA was extracted from ethylenediaminetetraacetic acid-treated blood using a commercial DNA extraction kit (QiAmp blood kit, Kagan). The triallelic APOE (⑀2-4) polymorphism was assessed with a single-stage polymerase chain reaction-based method and digestion with the restriction enzyme HhaI, as previously described. 28 
Statistical Analysis
The Hardy-Weinberg equilibrium was verified for all tested populations. Statistical analyses were performed using SigmaStat (version 1.0, Jandel Corp.). The chi-square test, an analysis of variance followed by Bonferroni correction for multiple comparisons, and the Student t-test were used to compare allele frequencies, genotype frequencies, and the clinical characteristics between cases and controls. According to recent guidelines for genetic association studies in neurological disorders, the level of statistical significance was set at a probability value less than 0.01.
2
Results
The distribution of genotypes and alleles conformed to the Hardy-Weinberg equilibrium. The genotype and allele frequencies of the APOE gene in our control group were remarkably similar to what has been reported in other Italian populations.
4,5 Table 2 shows the comparison of genotype and allele frequencies of the APOE gene in patients with aneurysmal SAH and healthy controls. There was no significant different between cases and controls for either genotype or allele frequencies ( 2 = 9.41, p = 0.094 and 2 = 0.3, p = 0.73, respectively). When the patients with SAH were stratified into clinical subgroups, multiple comparisons of allele and genotype frequencies showed no significant difference.
The clinical characteristics of patients with aneurysmal SAH according to APOE genotypes (⑀2⑀2, ⑀2⑀3, ⑀3⑀3, ⑀3⑀4, ⑀2⑀4, ⑀4⑀4) are shown in Table 3 . In comparison with the remaining genotypes, patients carrying the ⑀3⑀4 geno- Finally, we compared the clinical characteristics of patients with aneurysmal SAH carrying the APOE ⑀4 allele with those of noncarriers (⑀4Ϫ). Hunt and Hess grades were significantly lower in APOE ⑀4 carriers in comparison with noncarriers (t = Ϫ3.25, p = 0.0014). We found no significant intergroup difference in any of the remaining clinical features.
Discussion
In this study of an Italian population we found no evidence of a genetic association between APOE gene polymorphisms and the risk for aneurysmal SAH. Allele and genotype frequencies of APOE gene polymorphism were similarly distributed between patients and controls. Furthermore, when the patients were divided into different clinical subgroups, no significant difference in APOE allele and genotype frequencies was found in multiple comparisons.
It is therefore unlikely that genetic variations within the APOE gene greatly contribute to aneurysmal SAH susceptibility.
The results of our study agree with those of two previous molecular genetic studies, in which no association was found between the APOE gene and aneurysmal SAH, 23, 26 and suggest that alternative genes located in the 19q13 region should be examined as potential candidate genes for aneurysmal SAH. In addition, when we analyzed the clinical features of patients with SAH with respect to APOE genotypes, we found a modest effect of the APOE genotypes on the clinical characteristics of the disease: only Hunt and Hess grade at admission differed significantly between patients carrying the ⑀4 allele and noncarriers. Our data provide support for the idea that the APOE gene should be considered only a disease modifier gene and that it does not play a major role in aneurysmal SAH.
The neurobiological mechanisms underlying the effect of the APOE ⑀4 allele on the Hunt and Hess grading found in our patients with SAH are, at present, unknown. Apolipoprotein E is produced mainly in astrocytes and is responsible for the transportation of lipids within the brain. The
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Apolipoprotein E gene and aneurysmal subarachnoid hemorrhage 247 protein mediates neuronal protection, interactions with estrogens, and modulation of synaptic proteins. 9 Possession of the APOE ⑀4 allele has been shown to result in a greater propensity to develop age-related cognitive impairment, a decrease in the synapse/neuron ratio, and increased susceptibility to exogenous neurotoxins. 10 Taken together, these data suggest that patients with SAH carrying an APOE ⑀4 allele are more sensitive to the neuronal and oxidative damage induced by SAH.
Genetic association studies are becoming increasingly frequent in the medical literature and they are considered particularly useful to the deciphering of the genetic bases of complex diseases like aneurysmal SAH. However, association studies are vulnerable to several biases involving factors such as phenotypic definition of the disease, sample size of cases and controls, and population stratification. In our study, there are several points that reassure us regarding these issues. The diagnosis of aneurysmal SAH depends on clinical and radiological criteria that are unambiguous and precise. The allele and genotype frequencies of APOE gene polymorphism that we found in our control group were similar to those reported previously in other Italian populations. 4, 5 So, it is likely that cases and controls were derived from the same homogenous population. In addition, according to recent guidelines, we defined the level for statistical significance at a probability value less than 0.01 in order to exclude spurious associations.
2 Nevertheless, our study was hospital based, and it is well known that a percentage of patients with SAH die before admission to hospital. These patients represent a bias of our study, and excluding them may have led us to underestimate the role of APOE ⑀4 allele in the disease. Thus, considering the limits of genetic association studies and the clinical heterogeneity of aneurysmal SAH, additional data from different populations may be useful to definitely exclude a role for the APOE gene in aneurysmal SAH.
Conclusions
We found that, in an Italian population, the frequencies of APOE alleles and genotypes did not differ significantly between patients with aneurysmal SAH and healthy controls. In addition, we found that the ⑀4 allele of the APOE gene exerts a modest effect on the clinical characteristics of the disease. It is therefore unlikely that the APOE gene plays an important role in aneurysmal SAH.
